{
  "id": 2855624,
  "title": "AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?",
  "url": "https://urgent.news/2026/08/23/astrazeneca-made-a-1-5-billion-lung-cancer-bet-but-can-zegfrovy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-23T19:38:55.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-made-1-5-billion-193855181.html"
  },
  "original_language": "en",
  "account": "AstraZeneca has entered into a $1.5 billion deal to secure global rights to Zegfrovy, a targeted therapy for non-small cell lung cancer. The pharmaceutical giant will pay $600 million upfront and could receive an additional $900 million if Zegfrovy meets certain milestones. Dizal Pharmaceutical, the maker of Zegfrovy, will also receive tiered royalties on global sales. Zegfrovy is approved in the US and China for patients with specific EGFR mutations who have progressed after platinum-based chemotherapy. AstraZeneca will be responsible for the drug's development and commercialization. This acquisition bolsters AstraZeneca's oncology portfolio, which already includes Tagrisso, Imfinzi, and Enhertu. The product's approval in the US and China represents a significant milestone, and the company's global regulatory and commercial capabilities may extend its reach further. However, the deal's value hinges on Zegfrovy's ability to gain broader adoption beyond its targeted patient population and generate substantial revenue.",
  "summary": null,
  "key_points": [
    "AstraZeneca secures $1.5B rights to Zegfrovy lung cancer therapy.",
    "$600M upfront payment, $900M potential milestone payments.",
    "Zegfvy approved in US and China for EGFR mutation patients."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}